The ubiquitous mineralocorticoid receptor: Clinical implications

Current Hypertension Reports

Volumn 14, Issue 6, 2012, Pages 573-580

  Hawkins, Urseline A ^a,b   Gomez Sanchez, Elise P ^a,b   Gomez Sanchez, Clara M ^b   Gomez Sanchez, Celso E ^a,b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

(MR); Aldosterone; Blood pressure; Cardiac fibrosis; CHF; Congestive heart failure; Diabetes mellitus; Diabetic nephropathy; Glucocorticoids; Hyperkalemia; Hypertension; Metabolic syndrome; Mineralocorticoid receptor; Obesity; Primary aldosteronism; Sympathetic nerve activation; Thiazide diuretics; Thiazides

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; ALDOSTERONE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN II; CHLORTALIDONE; CORTICOSTERONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; FLUDROCORTISONE; HYDROCORTISONE; IRBESARTAN; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT;

ACUTE HEART INFARCTION; ADIPOSE TISSUE; AMINO ACID SEQUENCE; ARTICLE; BRAIN; CONGESTIVE HEART FAILURE; DEPRESSION; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE HYPERTROPHY; HIPPOCAMPUS; HUMAN; HYPERKALEMIA; HYPERTENSION; INSULIN RESISTANCE; KIDNEY FAILURE; NONHUMAN; OXIDATIVE STRESS; PRIMARY HYPERALDOSTERONISM; PROTEIN DOMAIN; PROTEIN EXPRESSION; QUALITY OF LIFE; RECEPTOR BINDING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; SYMPATHETIC NERVE;

ALDOSTERONE; CARDIOVASCULAR DISEASES; GLUCOCORTICOIDS; HUMANS; HYPERTENSION; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RECEPTORS, MINERALOCORTICOID; RENAL INSUFFICIENCY, CHRONIC;

EID: 84870488531     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-012-0297-0     Document Type: Article

References (98)

1. Simpson SA, Tait JF, Wettstein A, et al. Konstitution des aldosterons, des neuen mineralocorticoids. Experientia. 1953;10:132-3.
2. Conn JW. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med. 1955;45:3-7.
3. Funder JW. Aldosterone and mineralocorticoid receptors: a personal reflection. Mol Cell Endocrinol. 2012;350:146-50.
4. Funder JW, Feldman D, Edelman I. Specific Aldosterone binding in rat kidney and parotid. J Steroid Biochem. 1972;3:209-18.
5. Hood Jr. WG, Hill Jr. R, Pittman Jr. JA, Farmer Jr. TA. Studies on the metabolic effects of spironolactone in man. Ann N Y Acad Sci. 1960;88:864-80.
6. Arriza JW, Weinberger C, Cerelli G, et al. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science. 1987;237:268-75.
7. Viengchareun S, Le Menuet D, Martinerie L, et al. The mineralocorticoid receptor: insights into its molecular and (patho)physiological biology. Nucl Recept Signal. 2007;5:e012.
8. Farman N, Bonvalet JP. Aldosterone binding in isolated tubules. III. Autoradiography along the rat nephron. Am J Physiol. 1983;245:F606-614.
9. Farman N, Oblin ME, Lombes M, et al. Immunolocalization of gluco-and mineralocorticoid receptors in rabbit kidney. Am J Physiol. 1991;260:C226-233.
10. Funder JW. Mineralocorticoid receptors: distribution and activation. Heart Fail Rev. 2005;10:15-22.
11. Reul JMH, De Kloet ER. Two receptor systems for coticosterone in rat brain: microdistribution and differential occupation. Endocrinology. 1985;117:2505-11.
12. De Kloet ER, Vreugdenhil E, Oitzl MS, Joels M. Brain corticosteroid receptor balance in health and disease. Endocr Rev. 1998;19:269-301.
13. Gomez-Sanchez CE, de Rodriguez AF, Romero DG, et al. Development of a panel of monoclonal antibodies against the mineralocorticoid receptor. Endocrinology. 2006;147:1343-8.
14. Gomez-Sanchez EP. Brain mineralocorticoid receptors: orchestrators of hypertension and end-organ disease. Curr Opin Nephrol Hypertens. 2004;13:191-6.
15. Gomez-Sanchez EP, Gomez-Sanchez MT, de Rodriguez AF, et al. Immunohistochemical Demonstration of the Mineralocorticoid Receptor, 11{beta}-Hydroxysteroid Dehydrogenase-1 and -2, and Hexose-6-phosphate Dehydrogenase in Rat Ovary. J Histochem Cytochem. 2009;57:633-41.
16. Gomez-Sanchez CE, Warden M, Gomez-Sanchez MT, et al. Diverse immunostaining patterns of mineralocorticoid receptor monoclonal antibodies. Steroids. 2011;76:1541-5.
17. De Kloet ER, Versteeg DHG, Kovacs GL. Aldosterone blocks the response to corticosterone in the raphe-hippocampal serotonin system. Brain Res. 1983;264:323-7.
18. Funder J, Myles K. Exclusion of corticosterone from epithelial mineralocorticoid receptors is insufficient for selectivity of aldosterone action: in vivo binding studies. Endocrinology. 1996;137:5264-8.
19. Krozowski ZS, Funder JW. Renal mineralocorticoid receptors and hippocampal corticosterone-binding species have identical intrinsic steroid specificity. Proc Natl Acad Sci U S A. 1983;80:6056-60.
20. Funder JW, Pearce PT, Smith R, Smith AI. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science. 1988;242:583-5.
21. Edwards CRW, Burt D, McIntyre MA, et al. Localisation of 11bhydroxysteroid dehydrogenase-tissue specific protector of the mineralocorticoid receptor. Lancet. 1988;ii:986-9.
22. Stewart PM, Wallace AM, Valentino R, et al. Mineralocorticoid activity of liquorice: 11-Beta-hydroxysteroid dehydrogenase deficiency comes of age. Lancet. 1987;ii:821-4.
23. van Leeuwen N, Bellingrath S, de Kloet ER, et al. Human mineralocorticoid receptor (MR) gene haplotypes modulate MR expression and transactivation: implication for the stress response. Psychoneuroendocrinology. 2011;36:699-709.
24. Joels M, Karst H, DeRijk R, de Kloet ER. The coming out of the brain mineralocorticoid receptor. Trends Neurosci. 2008;31:1-7.
25. Gomez-Sanchez EP. The mammalian mineralocorticoid receptor: tying down a promiscuous receptor. Exp Physiol. 2010;95:13-8.
26. Grossmann C, Benesic A, Krug AW, et al. Human mineralocorticoid receptor expression renders cells responsive for nongenotropic aldosterone actions. Mol Endocrinol. 2005;19:1697-710.
27. Funder JW. The nongenomic actions of aldosterone. Endocr Rev. 2005;26:313-21.
28. Groeneweg FL, Karst H, de Kloet ER, Joels M. Mineralocorticoid and glucocorticoid receptors at the neuronal membrane, regulators of nongenomic corticosteroid signalling. Mol Cell Endocrinol. 2011.
29. Gros R, Ding Q, Sklar LA, et al. GPR30 expression is required for the mineralocorticoid receptor-independent rapid vascular effects of aldosterone. Hypertension. 2011;57:442-51.
30. Selye H, Hall CE. Production of nephrosclerosis and cardiac hypertrophy in the rat by desoxycorticosterone acetate overdosage. Am Heart J. 1943;27:338-44.
31. Weber KT, Brilla CG, Janicki JS. Myocardial fibrosis: functional significance and regulatory factors. Cardiovasc Res. 1993;27:341-8.
32. Robert V, Van Thiem N, Cheav SL, et al. Increased cardiac types I and III collagen mRNAs in aldosterone-salt hypertension. Hypertension. 1994;24:30-6.
33. Brilla CG, Matsubara LS, Weber KT. Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Card. 1993;71:12A-6A.
34. Rocha R, Rudolph AE, Frierdich GE, et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol. 2002;283:H1802-1810.
35. Rocha R, Stier CT, Kifor I, et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology. 2000;141:3871-8.
36. Young M, Fullerton M, Dilley R, Funder J. Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest. 1994;93:2578-83.
37. Gomez-Sanchez EP. Mineralocorticoid modulation of central control of blood pressure. Steroids. 1995;60:69-72.
38. Young MJ, Rickard AJ. Mechanisms of mineralocorticoid saltinduced hypertension and cardiac fibrosis. Mol Cell Endocrinol. 2012;350:248-55.
39. Pitt B. "Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovasc Drugs Ther. 1995;9:145-9.
40. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation. 1990;82:1730-6.
41. Rossi GP, Sacchetto A, Pavan E, et al. Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma. Circulation. 1997;95:1471-8.
42. Pitt B, Zannad F, Cody R, et al. The effect of spironolactone on mobidity and mortality in patients with severe heart failure. Randomized Aldactone evaluation study investigators. N Engl J Med. 1999;341:709-17.
43. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-21.
44. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11-21. This paper extended the benefit of the use of mineralocorticoid receptor antagonists in patients with mild systolic congestive heart failure.
45. Rossignol P, Menard J, Fay R, et al. Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy. J Am Coll Cardiol. 2011;58:1958-66. This study clarified that the beneficial effects of mineralocorticoid receptor antagonists were more direct rather than just as a potassium-sparing diuretic.
46. Pitt B, Reichek N, Willenbrock R, et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation. 2003;108:1831-8.
47. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351:543-51.
48. Desai AS, Lewis EF, Li R, et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. Am Heart J. 2011;162:966-72. e910.
49. Beygui F, Vicaut E, Ecollan P, et al. Rationale for an early aldosterone blockade in acute myocardial infarction and design of the ALBATROSS trial. Am Heart J. 2010;160:642-8.
50. Messaoudi S, Azibani F, Delcayre C, Jaisser F. Aldosterone, mineralocorticoid receptor, and heart failure. Mol Cell Endocrinol. 2012;350:266-72.
51. Mihailidou AS, Le Loan TY, Mardini M, Funder JW. Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction. Hypertension. 2009;54:1306-12.
52. Herrada AA, Campino C, Amador CA, et al. Aldosterone as a modulator of immunity: implications in the organ damage. J Hypertens. 2011;29:1684-92.
53. Rahmouni K, Barthelmebs M, Grima M, et al. Involvement of brain mineralocorticoid receptor in salt-enhanced hypertension in spontaneously hypertensive rats. Hypertension. 2001;38:902-6.
54. YoungMJ,Morgan J, Brolin K, et al. Activation ofmineralocorticoid receptors by exogenous glucocorticoids and the development of cardiovascular inflammatory responses in adrenalectomized rats. Endocrinology. 2010;151:2622-8.
55. Greene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest. 1996;98:1063-8.
56. Blasi ER, Rocha R, Rudolph AE, et al. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int. 2003;63:1791-800.
57. Bienvenu LA, Morgan J, Rickard AJ, et al. Macrophage mineralocorticoid receptor signaling plays a key role in aldosteroneindependent cardiac fibrosis. Endocrinology. 2012;153:3416-25.
58. Rickard AJ, Morgan J, Tesch G, et al. Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone/salt-induced cardiac fibrosis and increased blood pressure. Hypertension. 2009;54:537-43.
59. Shibata S, Fujita T. Mineralocorticoid receptors in the pathophysiology of chronic kidney diseases and the metabolic syndrome. Mol Cell Endocrinol. 2012;350:273-80. This is an excellent review of the mechanisms and clinical importance of mineralocorticoid receptor antagonists in kidney diseases, including diabetes and the metabolic syndrome.
60. Shibata H, Itoh H. Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension. Am J Hypertens. 2012.
61. Nishiyama A, Yao L, Fan Y, et al. Involvement of aldosterone and mineralocorticoid receptors in rat mesangial cell proliferation and deformability. Hypertension. 2005;45:710-6.
62. Guo C, Martinez-Vasquez D, Mendez GP, et al. Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus. Endocrinology. 2006;147:5363-73.
63. Nielsen SE, Persson F, Frandsen E, et al. Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study. Diabet Med. 2012. This study demonstrates the effects of spironolactone improving the excretion of markers of renal dysfunction.
64. Schjoedt KJ, Rossing K, Juhl TR, et al. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int. 2006;70:536-42.
65. Rossing K, Schjoedt KJ, Smidt UM, et al. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care. 2005;28:2106-12.
66. Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension. 2003;41:64-8.
67. Edwards NC, Steeds RP, Chue CD, et al. The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease. Br J Clin Pharmacol. 2012;73:447-54.
68. Penfornis P, Viengchareun S, Le Menuet D, et al. The mineralocorticoid receptor mediates aldosterone-induced differentiation ofT37i cells into brown adipocytes. Am J Physiol Endocrinol Metab. 2000;279:386-94.
69. Viengchareun S, Penfornis P, Zennaro MC, Lombes M. Mineralocorticoid and glucocorticoid receptors inhibit UCP expression and function in brown adipocytes. Am J Physiol Endocrinol Metab. 2001;280:E640-649.
70. Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, et al. Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci U S A. 2003;100:14211-6.
71. Ehrhart-Bornstein M, Arakelyan K, Krug AW, et al. Fat cells may be the obesity-hypertension link: human adipogenic factors stimulate aldosterone secretion from adrenocortical cells. Endocr Res. 2004;30:865-70.
72. Rossi GP, Sticchi D, Giuliani L, et al. Adiponectin receptor expression in the human adrenal cortex and aldosteroneproducing adenomas. Int J Mol Med. 2006;17:975-80.
73. Briones AM, Cat AN, Callera GE, et al. Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension. 2012;59:1069-78.
74. Kraus D, Jager J, Meier B, et al. Aldosterone inhibits uncoupling protein-1, induces insulin resistance, and stimulates proinflammatory adipokines in adipocytes. Horm Metab Res. 2005;37:455-9.
75. Guo C, Ricchiuti V, Lian BQ, et al. Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation. 2008;117:2253-61.
76. Caprio M, Antelmi A, Chetrite G, et al. Antiadipogenic effects of the mineralocorticoid receptor antagonist drospirenone: potential implications for the treatment of metabolic syndrome. Endocrinology. 2011;152:113-25.
77. Stumpf WE, Sar M. Glucocorticosteroids and mineralocorticosteroid hormone target sites in the brain. Autoradiographic studies with corticosterone, aldosterone, deoxycorticosterone: in interaction within the brain-pituitary- adrenocortical system. In: Jones MT, Gillham B, Dallman MF, Chattopadhyay S. Interactions within the Brain-Pituitary-Adrenocortical System. London, New York: Academic Press; 1979. pp. 137-147.
78. Gomez-Sanchez EP, Gomez-Sanchez CE. Central regulation of blood pressure by the mineralocorticoid receptor. Mol Cell Endocrinol. 2012;350:289-98.
79. Geerling JC, Engeland WC, Kawata M, Loewy AD. Aldosterone target neurons in the nucleus tractus solitarius drive sodium appetite. J Neurosci. 2006;26:411-7.
80. Sakai RR, Nicolaidis S, Epstein AN. Salt appetite is suppressed by interference with angiotensin II and aldosterone. Am J Physiol. 1986;251:R762-8.
81. Sakai RR, Ma LY, Zhang DM, et al. Intracerebral administration of mineralocorticoid receptor antisense oligonucleotides attenuate adrenal steroid-induced salt appetite in rats. Neuroendocrinology. 1996;64:425-9.
82. Kontak AC, Wang Z, Arbique D, et al. Reversible sympathetic overactivity in hypertensive patients with primary aldosteronism. J Clin Endocrinol Metab. 2010;95:4756-61.
83. Monahan KD, Leuenberger UA, Ray CA. Aldosterone impairs baroreflex sensitivity in healthy adults. Am J Physiol Heart Circ Physiol. 2007;292:H190-197.
84. Menon DV, Arbique D, Wang Z, et al. Differential effects of chlorthalidone versus spironolactone on muscle sympathetic nerve activity in hypertensive patients. J Clin Endocrinol Metab. 2009;94:1361-6.
85. Raheja P, Price A, Wang Z et al. Spironolactone Prevents Chlorthalidone-Induced Sympathetic Activation and Insulin Resistance in Hypertensive Patients. Hypertension. 2012;60:319-25. This study demonstrates the effects of spironolactone improving the excretion of markers of renal dysfunction.
86. De Kloet ER. Hormones and the stressed brain. Ann N YAcad Sci. 2004;1018:1-15.
87. Sukor N, Kogovsek C, Gordon RD, et al. Improved quality of life, blood pressure, and biochemical status following laparoscopic adrenalectomy for unilateral primary aldosteronism. J Clin Endocrinol Metab. 2010;95:1360-4.
88. Yagi S, Akaike M, Aihara K, et al. High plasma aldosterone concentration is a novel risk factor of cognitive impairment in patients with hypertension. Hypertens Res. 2011;34:74-8.
89. Sonino N, Fallo F, Fava GA. Psychological aspects of primary aldosteronism. Psychother Psychosom. 2006;75:327-30.
90. Emanuele E, Geroldi D, Minoretti P, et al. Increased plasma aldosterone in patients with clinical depression. Arch Med Res. 2005;36:544-8.
91. Gomez-Sanchez CE, Rossi GP, Fallo F, Mannelli M. Progress in primary aldosteronism: present challenges and perspectives. Horm Metab Res. 2010;42:374-81.
92. Gomez-Sanchez CE, Gomez-Sanchez EP. The protective side of the mineralocorticoid receptor. Endocrinology. 2012;153:1565-7.
93. Stranahan AM, Arumugam TV, Lee K, Mattson MP. Mineralocorticoid receptor activation restores medial perforant path LTP in diabetic rats. Synapse. 2010;64:528-32.
94. Otte C, Hinkelmann K, Moritz S, et al. Modulation of the mineralocorticoid receptor as add-on treatment in depression: a randomized, double-blind, placebo-controlled proof-of-concept study. J Psychiatr Res. 2010;44:339-46.
95. Goritz C, Frisen J. Neural stem cells and neurogenesis in the adult. Cell Stem Cell. 2012;10:657-9.
96. Munier M, Law F, Meduri G et al. Mineralocorticoid receptor overexpression facilitates differentiation and promotes survival of embryonic stem cell-derived neurons. Endocrinology. 2012.
97. Kolkhof P, Borden SA. Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics. Mol Cell Endocrinol. 2012;350:310-7. This is an excellent review of the pharmacology of mineralocorticoid receptor antagonists, old and new.
98. Wong TY, Mitchell P. Hypertensive retinopathy. N Engl J Med. 2004;351:2310-7.